These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation. Lentini NA; Foust BJ; Hsiao CC; Wiemer AJ; Wiemer DF J Med Chem; 2018 Oct; 61(19):8658-8669. PubMed ID: 30199251 [TBL] [Abstract][Full Text] [Related]
3. Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism. Shippy RR; Lin X; Agabiti SS; Li J; Zangari BM; Foust BJ; Poe MM; Hsiao CC; Vinogradova O; Wiemer DF; Wiemer AJ J Med Chem; 2017 Mar; 60(6):2373-2382. PubMed ID: 28218845 [TBL] [Abstract][Full Text] [Related]
4. A Photo-Crosslinkable Biotin Derivative of the Phosphoantigen (E)-4-Hydroxy-3-Methylbut-2-Enyl Diphosphate (HMBPP) Activates Vγ9Vδ2 T Cells and Binds to the HMBPP Site of BTN3A1. Mattarei A; Enzinger M; Gu S; Karunakaran MM; Kimmel B; Berner N; Adams EJ; Herrmann T; Amslinger S Chemistry; 2017 Sep; 23(49):11945-11954. PubMed ID: 28631855 [TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationships of Butyrophilin 3 Ligands. Wiemer AJ ChemMedChem; 2020 Jun; 15(12):1030-1039. PubMed ID: 32453919 [TBL] [Abstract][Full Text] [Related]
6. Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs. Foust BJ; Li J; Hsiao CC; Wiemer DF; Wiemer AJ ChemMedChem; 2019 Sep; 14(17):1597-1603. PubMed ID: 31226236 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol. Lentini NA; Schroeder CM; Harmon NM; Huang X; Schladetsch MA; Foust BJ; Poe MM; Hsiao CC; Wiemer AJ; Wiemer DF ACS Med Chem Lett; 2021 Jan; 12(1):136-142. PubMed ID: 33488975 [TBL] [Abstract][Full Text] [Related]
17. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727 [TBL] [Abstract][Full Text] [Related]
18. A Structural Change in Butyrophilin upon Phosphoantigen Binding Underlies Phosphoantigen-Mediated Vγ9Vδ2 T Cell Activation. Yang Y; Li L; Yuan L; Zhou X; Duan J; Xiao H; Cai N; Han S; Ma X; Liu W; Chen CC; Wang L; Li X; Chen J; Kang N; Chen J; Shen Z; Malwal SR; Liu W; Shi Y; Oldfield E; Guo RT; Zhang Y Immunity; 2019 Apr; 50(4):1043-1053.e5. PubMed ID: 30902636 [TBL] [Abstract][Full Text] [Related]
19. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives. Akinboye ES; Rosen MD; Bakare O; Denmeade SR Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549 [TBL] [Abstract][Full Text] [Related]
20. A new cyclopamine glucuronide prodrug with improved kinetics of drug release. Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]